Triple negative breast cancers are a poor prognosis breast cancer with limited therapeutic options as they do not express estrogen receptors, progesterone receptors or Her2. Recent clinical studies have shown that women who have triple negative breast cancers, but also express the alternate estrogen receptor, ERβ, respond well to Tamoxifen.
We will use our mouse model of triple negative breast cancer, engineered to express ERβ, to determine how Tamoxifen exerts its benefits to these patients. This project will involve RNA sequencing of tumours.
The Britt laboratory is interested in understanding what mediates breast cancer risk to develop novel treatments and preventatives.
We are interested in defining:
1. What changes occur within the breast during the earliest stages of cancer development.
2. What mediates the protection against breast cancer that is afforded by childbearing.
3. Why women with increased breast density are at an increased risk of breast cancer. https://www.petermac.org/research/labs/kara-britt
Peter MacCallum Cancer Centre, Melbourne Australia
Peter MacCallum Cancer Centre is Australia’s only public hospital solely dedicated to cancer, and home to the largest cancer research group in Australia. Cancer is a complex set of diseases, and modern cancer research institutes such as Peter Mac conduct research covering a diversity of topics that range from laboratory-based studies into the fundamental mechanisms of cell growth, translational studies that seek more accurate cancer diagnosis, clinical trials with novel treatments, and research aimed to improve supportive care.
All students engaged in postgraduate studies at Peter Mac are enrolled in the Comprehensive Cancer PhD (CCPhD) program, regardless of which university they are enrolled through. The program is managed by the Sir Peter MacCallum Department of Oncology (The University of Melbourne), based at Peter Mac.
Tapping into the depth and breadth of knowledge and experience offered by the ten partners of the Victorian Comprehensive Cancer Centre (VCCC) alliance, the University of Melbourne’s Comprehensive Cancer PhD Program provides a unique opportunity for multidisciplinary cancer-related PhD candidates to experience clinical and research activities across the alliance.
The Comprehensive Cancer PhD program builds on established conventional training for cancer research students providing a coordinated program of skills, research and career training in addition to usual PhD activities. The program is designed to complement existing PhD activities and provides opportunities to develop professional skills that will help candidates to fulfil their career ambitions. https://www.petermac.org/education/comprehensive-cancer-phd-program
All PhD students at Peter Mac must have a scholarship from The University of Melbourne or through another government, trust or philanthropic organisation. Before applying for a scholarship, you must have agreed on a project with an institute supervisor.
For further information about the university application process, see:
For further information regarding scholarships (both local and international), see:
Closing dates for applications for scholarships to commence in 2019: Round 1 -31 October 2018; Round 2 - 28 Nov 2018; Round 3 - 20 Feb 2019.